Sciclone: China Drug Price Cuts Below Projections
From Associated Press (September 18, 2012)
FOSTER CITY, Calif. -- SciClone Pharmaceuticals Inc. said Tuesday that the government of China has cut the price of its hepatitis and cancer drug Zadaxin.
However SciClone said the cut will have a smaller-than-expected effect on its revenue and profit margins. The company’s shares advanced 58 cents, or 12.4 percent, to close at $5.27 on Tuesday.
SciClone said the retail price of Zadaxin is being cut by 18 percent, but the company’s margins and revenue will be reduced by less than 5 percent, because most of the costs will be borne by its importation and distribution network. SciClone said it had expected a reduction of 7 to 8 percent.
The company also said the price reductions for its cardiology
drug Aggrastat and several drugs SciClone markets in China for
Pfizer Inc. and Baxter International Inc. were smaller than
Posted: September 2012